Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions
Hayley L. Rein(University of Pittsburgh), Kara A. Bernstein(Columbia University Irving Medical Center), Kristie Darrah(University of Pittsburgh), Sarah R Hengel(Tufts University), Eric C. Greene(Columbia University Irving Medical Center), Yashpal Rawal(The University of Texas at San Antonio Health Science Center), Shaun K. Olsen(The University of Texas at San Antonio Health Science Center), Susan M. Domchek(University City Science Center), Marc R. Radke(University of Washington), Jung‐Min Lee(National Cancer Institute), Reagan A Russell(University of Pittsburgh), Elizabeth M. Swisher(University of Washington), Judith L. Yanowitz(University of Pittsburgh), Patrick Sung(The University of Texas at San Antonio Health Science Center), Mohammad Afsar(The University of Texas at San Antonio Health Science Center), Meghan R. Sullivan(University of Pittsburgh), Patricia L. Opresko(UPMC Hillman Cancer Center), Anna L Palovcak-Lightbourn(University of Pennsylvania), Phoebe S. Parker(University of Pennsylvania)
Cited by 8
Related Papers
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9
|Nature|2014|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660